Identification

Name
Moclobemide
Accession Number
DB01171
Description

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs). Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants [A3901].

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 268.739
Monoisotopic: 268.097855505
Chemical Formula
C13H17ClN2O2
Synonyms
  • 4-Chlor-N-(2-morpholinoethyl)benzamid
  • Moclobemid
  • Moclobemida
  • Moclobemide
  • Moclobemidum
  • p-Chloro-N-(2-morpholinoethyl)benzamide
External IDs
  • GNF-PF-695
  • RO 11-1163/000
  • RO-11-1163/000
  • RO-111163000

Pharmacology

Indication

For the treatment of major depressive disorder and bipolar disorder 1.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

A selective, reversible inhibitor of monoamine oxidase (MAO) which increases the 1. Besides its presence in sympathetic nerves, there is an abundant evidence that MAO-A is localized in noradrenergic neurons in the locus coeruleus and MAO-B is closely associated with serotonergic neurons of the raphe nucleus 1.

Mechanism of action

The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms 1,2.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
antagonist
inhibitor
Humans
UMonoamine oxidase
antagonist
Humans
UAmine oxidase [flavin-containing] B
antagonist
Humans
Absorption

Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first-pass metabolism reduces bioavailability to about 56% following administration of one dose, but increases to 90% with steady-state dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 0.3 - 1 hours following oral administration with a terminal half-life of 1.6h 4.

Volume of distribution

1-1.5 L/Kg 4

Protein binding

Approximately 50% (primarily to albumin) 4

Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6. Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6 [A3901].

Hover over products below to view reaction partners

Route of elimination

Moclobemide is almost completely renally excreted 4.

Half-life

1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

Clearance

Clearance of 30-78 L/h 4, mainly excreted in urine.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures 3. The effects of moclobemide alone in overdose are negligible, even with high volume ingestion. However, moclobemide overdose with a serotonergic agent (even in small, therapeutic doses) can cause severe serotonin toxicity. The elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses 3.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe metabolism of Moclobemide can be increased when combined with Abatacept.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Abciximab.
AbirateroneThe metabolism of Moclobemide can be decreased when combined with Abiraterone.
AcarboseMoclobemide may increase the hypoglycemic activities of Acarbose.
AcebutololMoclobemide may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Moclobemide is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when Moclobemide is combined with Acemetacin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Moclobemide.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Moclobemide.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Moclobemide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid excessive or chronic alcohol consumption.
  • Avoid tyramine-containing foods and supplements. Avoid excess consumption (<100mg) of tyramine. Food that contains tyramine includes yogurt, aged cheese, ripe bananas, wine, and sourdough bread.
  • Take after a meal.

Products

International/Other Brands
Aurorix
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ManerixTabletOralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada flag
ManerixTabletOralValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada flag
Manerix Tab 100mgTabletOralHoffmann La Roche1992-12-311997-12-04Canada flag
MoclobemideTabletOralAa Pharma Inc1997-09-18Not applicableCanada flag
MoclobemideTabletOralAa Pharma Inc1997-09-18Not applicableCanada flag
MoclobemideTabletOralAa Pharma Inc1999-07-14Not applicableCanada flag
Moclobemide-100TabletOralPro Doc Limitee1998-06-022009-07-23Canada flag
Moclobemide-150TabletOralPro Doc Limitee1998-06-022009-07-23Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Dom-moclobemide Tablets 150mgTabletOralDominion Pharmacal2001-02-152016-10-26Canada flag
Dom-moclobemide Tablets 300mgTabletOralDominion Pharmacal2001-02-152016-10-26Canada flag
Nu-moclobemideTabletOralNu Pharm Inc1998-07-282012-09-04Canada flag
Nu-moclobemideTabletOralNu Pharm Inc1998-07-292012-09-04Canada flag
PMS-moclobemideTabletOralPharmascience Inc2001-01-08Not applicableCanada flag
PMS-moclobemideTabletOralPharmascience Inc2001-01-08Not applicableCanada flag
Ratio-moclobemide - Tab 150mgTabletOralRatiopharm Inc Division Of Teva Canada Limited1997-10-012006-08-04Canada flag
Ratio-moclobemide - Tab 300mgTabletOralRatiopharm Inc Division Of Teva Canada Limited1999-07-122006-08-04Canada flag
Riva-moclobemide 150mg TabletsTabletOralLaboratoire Riva Inc1999-08-302003-07-28Canada flag
Riva-moclobemide 300mg TabletsTabletOralLaboratoire Riva Inc1999-08-302003-07-28Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
N06AG02 — Moclobemide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
4-halobenzoic acids and derivatives
Alternative Parents
Benzamides / Benzoyl derivatives / Chlorobenzenes / Morpholines / Aryl chlorides / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives / Oxacyclic compounds / Dialkyl ethers
show 5 more
Substituents
4-halobenzoic acid or derivatives / Amine / Amino acid or derivatives / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzamide / Benzoyl / Carboxamide group
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
benzamides, monochlorobenzenes, morpholines (CHEBI:83531)

Chemical Identifiers

UNII
PJ0Y7AZB63
CAS number
71320-77-9
InChI Key
YHXISWVBGDMDLQ-UHFFFAOYSA-N
InChI
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
IUPAC Name
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
SMILES
ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1

References

General References
  1. Bonnet U: Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. [PubMed:12595913]
  2. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K: Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7. doi: 10.1016/0009-9236(95)90230-9. [PubMed:7781267]
  3. Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ: Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003 Oct;56(4):441-50. [PubMed:12968990]
  4. Monamine Oxidase Inhibitors [Link]
  5. Citalopram [Link]
Human Metabolome Database
HMDB0015302
KEGG Drug
D02561
PubChem Compound
4235
PubChem Substance
46504667
ChemSpider
4087
BindingDB
15613
RxNav
30121
ChEBI
83531
ChEMBL
CHEMBL86304
ZINC
ZINC000019606670
Therapeutic Targets Database
DAP000576
PharmGKB
PA452615
Wikipedia
Moclobemide
AHFS Codes
  • 28:16.04.12 — Monoamine Oxidase Inhibitors

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentClozapine-induced Hypersalivation1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenia1
2CompletedTreatmentNicotine Dependence1
2TerminatedTreatmentAddictions1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral150 mg
Tablet, coated150 mg
Tablet, coated300 mg
Tablet
Tablet, film coatedOral150 MG
Tablet, film coatedOral300 MG
Tablet, film coatedOral
TabletOral
Prices
Unit descriptionCostUnit
Manerix 300 mg Tablet1.34USD tablet
Apo-Moclobemide 300 mg Tablet0.75USD tablet
Novo-Moclobemide 300 mg Tablet0.75USD tablet
Pms-Moclobemide 300 mg Tablet0.75USD tablet
Manerix 150 mg Tablet0.68USD tablet
Apo-Moclobemide 150 mg Tablet0.38USD tablet
Novo-Moclobemide 150 mg Tablet0.38USD tablet
Pms-Moclobemide 150 mg Tablet0.38USD tablet
Apo-Moclobemide 100 mg Tablet0.26USD tablet
Novo-Moclobemide 100 mg Tablet0.26USD tablet
Nu-Moclobemide 100 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)132[L1357]
boiling point (°C)377[L1357]
water solubility3.52e-04[L1357]
logP10.6[L1357]
pKa10.6 (ethanol-air)[L1357]
Predicted Properties
PropertyValueSource
Water Solubility1.12 mg/mLALOGPS
logP1.56ALOGPS
logP1.45ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.73ChemAxon
pKa (Strongest Basic)6.02ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity71.93 m3·mol-1ChemAxon
Polarizability28.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9691
Caco-2 permeable-0.5602
P-glycoprotein substrateSubstrate0.6652
P-glycoprotein inhibitor IInhibitor0.6892
P-glycoprotein inhibitor IINon-inhibitor0.8637
Renal organic cation transporterNon-inhibitor0.5691
CYP450 2C9 substrateNon-substrate0.8538
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5723
CYP450 1A2 substrateNon-inhibitor0.9138
CYP450 2C9 inhibitorNon-inhibitor0.8989
CYP450 2D6 inhibitorNon-inhibitor0.8081
CYP450 2C19 inhibitorInhibitor0.8024
CYP450 3A4 inhibitorNon-inhibitor0.9384
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5956
Ames testNon AMES toxic0.6867
CarcinogenicityNon-carcinogens0.8727
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.6098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7135
hERG inhibition (predictor II)Inhibitor0.5646
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-2900000000-c3230d46878446405991
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-3436435ae42cfbae36f0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-ebaa843d45c4c64c1d3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0970000000-ab2fbe8b1feae9ff3141
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e3243f45e1029a4c0e71
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-927950435244f3ac04e4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-6fe640038cbc911e2bae
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-26e37ce9ba0b814b7409
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-07e0ca3dba489a2810ec
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0980000000-70103607e1e68c966be9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-ac7d3f04849dde0da3d2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001r-0900000000-6634fb6b07312ce02ee6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-c43f4a856e6d225766ef
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-1231bd387729155af4ab
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-a885de4ee2be84e3748d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lr-0950000000-2942178c074461702181
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0019-2900000000-bf1e7c693c96e9a69966

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16. [PubMed:1705137]
  3. Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 Sep;52(3):450-74. [PubMed:8875133]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...

Components:
References
  1. Bonnet U: Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. [PubMed:12595913]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Bonnet U: Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. [PubMed:12595913]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Fisar Z, Hroudova J, Raboch J: Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645-56. [PubMed:21200377]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K: Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7. doi: 10.1016/0009-9236(95)90230-9. [PubMed:7781267]
  2. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, Shin SG: Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73. doi: 10.1067/mcp.2001.114231. [PubMed:11309556]
  3. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C: The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol. 1996 Aug;6(3):225-30. [PubMed:8880082]
  2. Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C: Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology (Berl). 1998 Jan;135(1):22-6. [PubMed:9489930]
  3. Flockhart Table of Drug Interactions [Link]
  4. Health Canada Approved Drug Products: Manerix (Moclobemide) tablets [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]

Drug created on June 13, 2005 07:24 / Updated on October 26, 2020 22:41

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates